Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5400)
All Articles published online
|
Publishing Process of This Article
|
May 7, 2014 (publication date) through Sep 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Yu JP, Sun SP, Sun ZQ, Ni XC, Wang J, Li Y, Hu LJ, Li DQ. Clinical trial of thalidomide combined with radiotherapy in patients with esophageal cancer. World J Gastroenterol 2014; 20(17): 5098-5103 [PMID: 24803825 DOI: 10.3748/wjg.v20.i17.5098] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i17/5098.htm |
| Number | Citing Articles |
| 1 |
Leifeng Liang, Zhibing Liu, Haisheng Zhu, Hongqian Wang, Yan Wei, Xuejian Ning, Zhiling Shi, Liujun Jiang, Zhan Lin, Haolin Yan, Rensheng Wang, Kai Hu. Efficacy and safety of thalidomide in preventing oral mucositis in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: A multicenter, open‐label, randomized controlled trial. Cancer 2022; 128(7): 1467 doi: 10.1002/cncr.34074
|
| 2 |
Jian Wang, Jing-Ping Yu, Xin-Chu Ni, Zhi-Qiang Sun, Wei Sun, Bin Nie, Su-Ping Sun, Jian-Lin Wang. Pathological response and serum VEGF changes during chemoradiotherapy for esophageal carcinoma. Medicine 2019; 98(20): e15627 doi: 10.1097/MD.0000000000015627
|
| 3 |
Jian Wang, Jingping Yu, Jianlin Wang, Xinchu Ni, Zhiqiang Sun, Wei Sun, Suping Sun, Yuting Lu. Thalidomide combined with chemo‑radiotherapy for treating esophageal cancer: A randomized controlled study. Oncology Letters 2019; doi: 10.3892/ol.2019.10354
|
| 4 |
Zijing Liu, Qin Zhao, Zhuangzhuang Zheng, Shiyu Liu, Lingbin Meng, Lihua Dong, Xin Jiang. Vascular normalization in immunotherapy: A promising mechanisms combined with radiotherapy. Biomedicine & Pharmacotherapy 2021; 139: 111607 doi: 10.1016/j.biopha.2021.111607
|
| 5 |
Mohammad Javed Ansari, Dmitry Bokov, Alexander Markov, Abduladheem Turki Jalil, Mohammed Nader Shalaby, Wanich Suksatan, Supat Chupradit, Hasan S. AL-Ghamdi, Navid Shomali, Amir Zamani, Ali Mohammadi, Mehdi Dadashpour. Cancer combination therapies by angiogenesis inhibitors; a comprehensive review. Cell Communication and Signaling 2022; 20(1) doi: 10.1186/s12964-022-00838-y
|
| 6 |
Yao Cheng, Zhe Qiao, Chengxue Dang, Bin Zhou, Shaomin Li, Wei Zhang, Jiantao Jiang, Yongchun Song, Jin Zhang, Dongmei Diao. p38 predicts depression and poor outcome in esophageal cancer. Oncology Letters 2017; doi: 10.3892/ol.2017.7129
|
| 7 |
Lijun Hu, Fei Sun, Zhiqiang Sun, Xinchu Ni, Jian Wang, Jianlin Wang, Mengyun Zhou, Yue Feng, Ze Kong, Qiu Hua, Jingping Yu. Apatinib enhances the radiosensitivity of the esophageal cancer cell line KYSE‑150 by inducing apoptosis and cell cycle redistribution. Oncology Letters 2018; doi: 10.3892/ol.2018.9803
|
| 8 |
Liyang Liu, Wusong Xue. Thalidomide suppresses migration and invasion of colorectal cancer cells by inhibiting HOXB7‐mediated activation of the Wnt/β‐catenin signaling pathway. Chemical Biology & Drug Design 2024; 103(1) doi: 10.1111/cbdd.14434
|
| 9 |
Virginia Di Paolo, Marta Colletti, Valentina Ferruzzi, Ida Russo, Angela Galardi, Iside Alessi , Giuseppe Maria Milano, Angela Di Giannatale. Circulating Biomarkers for Tumor Angiogenesis: Where Are We?. Current Medicinal Chemistry 2020; 27(14): 2361 doi: 10.2174/0929867325666180821151409
|
| 10 |
Gedefaw Getnet Amare, Birhanu Geta Meharie, Yaschilal Muche Belayneh. A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide. Journal of Oncology Pharmacy Practice 2021; 27(3): 673 doi: 10.1177/1078155220975825
|
| 11 |
Shi Zhou, Haijun Zhang. Synergies of Targeting Angiogenesis and Immune Checkpoints in Cancer: From Mechanism to Clinical Applications. Anti-Cancer Agents in Medicinal Chemistry 2020; 20(7): 768 doi: 10.2174/1871520620666200207091653
|